Granules India reports completion of FDA inspection with zero observations
Granules India outlines the inspection outcome and operational role of its U.S. subsidiary
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
FDA inspection
Shilpa Pharma Lifesciences’ Raichur API facility clears second consecutive FDA inspection with no…
Shilpa Medicare's Unit-2 API facility in Raichur, India passes March 2025 FDA audit without Form 483 observations, reinforcing…
Granules India’s Gagillapur facility classified as “Official Action Indicated” following US FDA…
Company responds to observations and initiates improvements in collaboration with external experts
Wanbury’s Patalganga manufacturing facility clears U.S. FDA inspection with zero observations
The inspection was conducted for four days